| 发明名称 | Use of <i>Lactobacillus </i>for treatment of autoimmune diseases | ||
| 摘要 | The present technology relates to the use of at least one strain of probiotic bacteria selected from Lactobacillus for the manufacture of a medicament for the treatment and/or prevention of an autoimmune disease. | ||
| 申请公布号 | US8936783(B2) | 申请公布日期 | 2015.01.20 |
| 申请号 | US200611992483 | 申请日期 | 2006.10.06 |
| 申请人 | Probi AB | 发明人 | Alenfall Jan;Berggren Anna;Rask Carola;Wold Agnes;Aghaibeik-Lavasani Shahram |
| 分类号 | A01N63/00;A61K39/02;C12N1/12;A23L1/30;A21D2/26;A21D8/04;A21D13/00;A23C9/123;A23L1/03;A23L1/10;A23L2/52;A61K35/74;C12R1/225;C12R1/25 | 主分类号 | A01N63/00 |
| 代理机构 | Buchanan Ingersoll & Rooney PC | 代理人 | Buchanan Ingersoll & Rooney PC |
| 主权项 | 1. A method of treating multiple sclerosis comprising administering to an individual having multiple sclerosis a sufficient amount of at least one isolated strain of probiotic Lactobacillus selected from the group consisting of Lactobacillus plantarum HEAL 9 deposited as DSM 15312, Lactobacillus plantarum HEAL 19 deposited as DSM 15313, and Lactobacillus paracasei 8700:2 deposited as DSM 13434. | ||
| 地址 | Lund SE | ||